Hemostemix’s Expands its Marketing Team Focused on Sales in Florida
Hemostemix Inc. (TSX-V: HEM; OTCQB: HMTXF; FSE: 2VF0), an autologous stem cell company developing and commercializing VesCell™ (ACP-01), announces the appointment of a seasoned commercial team encompassing marketing, sales, e-commerce and patient care communications, in compliance with federal and state regulations. The appointments enable Hemostemix to sell VesCell™ in Florida to podiatrist and vascular surgeons, to treat PAD & CLTI; and to cardiologist to treat Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and Congestive Heart Failure.
The additions to the leadership team are top-tier talent with a proven track record of success in the biopharmaceutical industry:
- Croom Lawrence, Chief Commercial Officer:
- With over 25 years of biotech commercial launch experience, Mr. Lawrence is a veteran in building high performing commercial teams and launching breakthrough therapies. Lawrence has supported 15+ blockbuster launches including global platform brands with multiple indications from Humira ($8B), Rinvoq ($6B), to Dupixent ($3B). Lawrence has generated hundreds of millions in return on marketing investment (ROMI) for Fortune 100 biotech clients, including Merck, BMS, Amgen, and Pfizer/Wyeth. Lawrence has recently been recognized with a PM360 Innovation Award in 2025 for a cognitive testing startup, Acurist.AI.
- Sana Farooqui, Fractional Chief Marketing Officer:
- A seasoned digital strategist and marketing professional, Farooqui will lead the company’s digital and social marketing efforts. She will direct messaging across key channels of influence to physicians, patients, and investors, ensuring the VesCell™ message is impactful, compliant, and aligned with Hemostemix’s mission.
- With 20+ years of full-funnel medical marketing and media experience from top health communications agencies, Branch will be instrumental in developing and delivering insight-led, omnichannel go-to-market strategies. He has deep experience working with industry leaders like AbbVie, Novartis, Merck on dozens of brands in cardiovascular, neurology, and dermatology, making him an ideal fit to drive media strategies that connect key audiences with VesCell’s benefits.
Under Florida’s Right-to-Try statute (SB 1768), physicians—including podiatrists, cardiologists, and all specialists treating pain and no-option patients suffering from PAD, CLTI, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, and congestive heart failure can offer VesCell™, Hemostemix’s patented ACP-01 therapy, to qualifying patients, following informed consent.
- Podiatrists & Vascular Surgeons – Improve Limb Circulation & Prevent Amputation:
- In three published trials, including Phase II, VesCell™ generated new circulation to restore blood flow, healed ulcers, and reduced the need for amputation.
- Cardiologists – Restore Cardiac Function:
- In four published studies of 24, 41, 106 and 53 subjects, VesCell™ increased ejection fraction, reduced severe angina, improved exercise capacity, and improved quality of life in patients suffering from angina, ischemic and non ischemic dilated cardiomyopathy, respectively.
- (Future) Neurologists – Address Vascular Dementia:
- Early human results suggest persistent cognitive benefits in vascular dementia for over 10 years in one patient treated with VesCell™.
“Hemostemix’s new outreach team is tasked with ensuring every eligible Florida practitioner knows the science, the law, and how VesCell™ works for their patients. This team’s collective experience of translating VesCell™ published outcomes into a clear, compelling messaging for a variety of audiences enables us to reach these cohorts of patients who suffer in pain,” stated Thomas Smeenk, CEO.